FDA NDA · NDA022177

STAVUDINE; LAMIVUDINE; NEVIRAPINE

Sponsor: STRIDES ACROLAB

APPLICATION

NDA022177

TYPE

NDA

ROUTE

ORAL

DOSAGE FORM

TABLET

MARKETING STATUS

None (Tentative Approval)

Products

STAVUDINE; LAMIVUDINE; NEVIRAPINENone (Tentative Approval)

STAVUDINE 30MG, LAMIVUDINE 150MG, NEVIRAPINE 200MG · TABLET · ORAL

2008-03-20Type 4 - New Combination · Original · priority — Letter ↗TA

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.